|
Adenocarcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
In addition, adenocarcinoma showed significantly higher incidence of concomitant expression of Ha-ras p21 and fes P85 as compared with other histologic types of lung cancer.
|
1310887 |
1992 |
|
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Binding of CD95 Ligand to CD95 on glioblastoma cells recruits the Src family member Yes and the p85 subunit of phosphatidylinositol 3-kinase to CD95, which signal invasion via the glycogen synthase kinase 3-beta pathway and subsequent expression of matrix metalloproteinases.
|
18328427 |
2008 |
|
Alzheimer's Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
For EHT 0202 or other AD drugs, such biomarkers may help to improve strategies to better identify appropriate patient populations for treatment, understand the drug mechanism of efficacy, and/or clarify the inherent subjectivity in most clinical endpoints used in this disease.
|
23234880 |
2013 |
|
Autoimmune Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
In the patients responding to EHT 0202, a pre-treatment (baseline) transcriptomic signature showed activation of pathways related to AD, CNS disorders, diabetes, inflammation, and autoimmunity, while a post-treatment signature indicated reduced activation of these pathways with induced metabolic and transcription stimulation.
|
23234880 |
2013 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Furthermore, EHT 1864 inhibited estrogen-induced cell proliferation in breast cancer cells and decreased tamoxifen-resistant breast cancer cell growth.
|
21118977 |
2011 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Overall, our data indicate that the p85 subunit is a valid target for therapeutic approaches and suggest that the structure of the peptide used in our study could be utilized for the development of novel drugs to apply in combination with therapies that fail to cure BCs with high PI3K activity.
|
23222510 |
2012 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In this study, we demonstrate that a formulation containing the block copolymer Pluronic P85 and antineoplastic drug doxorubicin (Dox) prevents the development of multidrug resistance in the human breast carcinoma cell line, MCF7.
|
16579640 |
2006 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer.
|
28027535 |
2017 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
We report that Mtgr1(-/-) mice were protected from tumorigenesis when injected with azoxymethane (AOM) and then subjected to repeated cycles of dextran sodium sulfate (DSS).
|
21303973 |
2011 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Overall our data indicates that MTGR1 has a context-dependent effect on intestinal tumorigenesis.
|
27270437 |
2016 |
|
Carcinogenesis
|
0.030 |
GeneticVariation
|
phenotype |
BEFREE |
These findings lend new insight to how changes in p85 gene dosage or mutations in p85 could lead to the hyper-activation of PI3K and thus contribute towards tumorigenesis.
|
16131837 |
2005 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, adenocarcinoma showed significantly higher incidence of concomitant expression of Ha-ras p21 and fes P85 as compared with other histologic types of lung cancer.
|
1310887 |
1992 |
|
Cerebrovascular accident
|
0.010 |
Biomarker
|
group |
BEFREE |
We conclude that variations of the REN (or of a nearby) gene that may be in linkage disequilibrium with REN (BglI(-)/MboI(+)) and (BglI(+)/MboI(+)) alleles could play a role in contributing to increased individual's genetic susceptibility to EHT and to stroke.
|
11224002 |
2001 |
|
Childhood Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Binding of CD95 Ligand to CD95 on glioblastoma cells recruits the Src family member Yes and the p85 subunit of phosphatidylinositol 3-kinase to CD95, which signal invasion via the glycogen synthase kinase 3-beta pathway and subsequent expression of matrix metalloproteinases.
|
18328427 |
2008 |
|
Childhood Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The observed repression of MTG16/MTGR1 promoters by the leukemia associated AML1-ETO fusion gene may have a role in hematopoietic dysfunction of leukemia.
|
22443175 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We determined which catalytic subunits of phosphoinositide 3-kinase (PI3K) were in active complex with the p85 regulatory subunit and showed enrichment for the α subunit in three CLLs carrying PIK3CA amplification.
|
22623730 |
2012 |
|
Colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
MTGR1 is required for tumorigenesis in the murine AOM/DSS colitis-associated carcinoma model.
|
21303973 |
2011 |
|
Colon Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Using this panel, we characterized two mutants of p85 (70 and 50 kDa) expressed in the human colon carcinoma cell line, HCC2998.
|
7541019 |
1995 |
|
Colon Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
A new delivery system, pluronic P85 block copolymers, conveying chemotherapeutic agent 5-fluorouracil (5-Fu) for inhibiting growth and metastasis of colon cancer was designed and developed.
|
26864651 |
2016 |
|
Colorectal Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, in human colorectal cancer (CRC) samples MTGR1 was downregulated at both the transcript and protein level.
|
27270437 |
2016 |
|
Colorectal Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
DC-SIGN activation recruited Lyn and p85 to form the DC-SIGN-Lyn-p85 complex, which promoted CRC metastasis by increasing PI3K/Akt/β-catenin signaling in tyrosine kinase Lyn-dependent manner.
|
31217502 |
2020 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our data suggest that CBFA2T2 expression correlates with aggressive characteristics of RCC and CBFA2T2 is required for maintenance of "stemness" through regulation of stem cells factors, thereby highlighting CBFA2T2 as a potential therapeutic target for RCC treatment.
|
29162985 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In the current study, anticancer activity of a novel heterodinuclear Cu(II)-Mn(II) complex (Schiff base-SB) in combination with poly(ethylene oxide) and poly(propylene oxide) block copolymer (pluronic) P85 was tested against RCC.
|
29288416 |
2018 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Correction to: CBFA2T2 is associated with a cancer stem cell state in renal cell carcinoma.
|
29782581 |
2018 |
|
Developmental delay (disorder)
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
By using 5-bromo-2-deoxyuridine (BrdU) labeling, we reveal that overexpression of P85 extended the cell cycle duration, which may result in developmental retardation during mouse corticogenesis.
|
29953879 |
2018 |